What is Biohaven's market cap?

Biohaven (BHVN) has a market capitalization of $2.2B and trades on NYSE.

Who are Biohaven's competitors?

Biohaven's key competitors include Eli Lilly and Company, Passage Bio, Inc. Common Stock, Vyome Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Biohaven partner with?

Biohaven's notable partners include Pfizer Inc..

What subsidiaries does Biohaven have?

Biohaven's subsidiaries include Biohaven Pharmaceuticals Inc..

Where is Biohaven headquartered?

Biohaven is headquartered in United States of America and employs approximately 239 people. It has been publicly traded since 2022.

Biohaven

BHVN

Biohaven is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies for immunology, neuroscience, and oncology.

Market cap

$2.18B+37.1%

Net income-$647.7M+27.1%

Free cash flow-$594.5M+8.4%

EPS (diluted)-$5.58+39.9%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 4, 2026

EPS-$0.88Miss by $0.02

Read the full report

Next report

Aug 10, 2026 (In 1 week)

Revenue estimate$490.5K

EPS estimate-$0.77

Financials

Q1 2026

Income statement

See full

Operating income-$130.4M+41.1%

Net income-$130.5M+41.1%

EPS (diluted)-$0.88+59.4%

Balance sheet

See full

Cash & equivalents$277.1M+170%

Total debt$286.2M+706%

Total equity$129.5M-50.1%

Total assets$466.4M+1.6%

Cash flow

See full

Operating cash flow-$149.9M+9.2%

CapEx--100%

Free cash flow-$149.9M+9.5%

Valuation & ratios

Valuation

See full

Market cap$2.18B+37.1%

Enterprise value$2.19B+50.8%

Returns & leverage

See full

Return on equity-333%+17.9pp

Debt / equity2.2×+2.1×

Current ratio7.4×+5.1×

Competitors

By market cap

Eli Lilly$1.07T+47.2%

Kymera Therapeutics$9.1B+192%

Biohaven$2.2B+63.9%

ProShares UltraPro Short NASDAQ Biotechnology$2.1B+201%

Avalo Therapeutics$1.0B+1,348%

PAS

Passage Bio, Inc.$14.8M-32.5%

HIN

Vyome Holdings, Inc.$14.0M—

GT Biopharma$12.0M+75.3%

By revenue growth

Eli Lilly+47.4%

Kymera Therapeutics-12.6%

By net margin

Eli Lilly34.99%+12.3pp

Kymera Therapeutics-611.96%-203pp

Avalo Therapeutics-7,965.76%—

Profile

Biohaven is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies for immunology, neuroscience, and oncology. The company leverages proprietary drug development platforms, including extracellular protein degradation, to advance a diverse pipeline of treatments for high-unmet-need conditions such as epilepsy and metabolic disorders.

Competitive position

A late-stage clinical developer focused on high-value therapeutic areas following its spin-off from its former parent company.

GeographiesGlobal

Customer segmentsHealthcare providers, Patients

Business modelR&D intensive, IP licensing, Drug development

SuppliersContract manufacturing organizations, Clinical research organizations, Academic research institutions

CustomersHospitals, Specialty pharmacies, Wholesale distributors

CountryUnited States of America

Listed2022

Employees239.0

CEOVladimir Coric

SectorHealthcare

IndustryBiotechnology

Websitebiohavenpharma.com

FilingsSEC EDGAR

Questions, answered.

What is Biohaven's market cap?: Biohaven (BHVN) has a market capitalization of $2.2B and trades on NYSE.
Who are Biohaven's competitors?: Biohaven's key competitors include Eli Lilly and Company, Passage Bio, Inc. Common Stock, Vyome Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Biohaven partner with?: Biohaven's notable partners include Pfizer Inc..
What subsidiaries does Biohaven have?: Biohaven's subsidiaries include Biohaven Pharmaceuticals Inc..
Where is Biohaven headquartered?: Biohaven is headquartered in United States of America and employs approximately 239 people. It has been publicly traded since 2022.